CD63-positive extracellular vesicles are potential diagnostic biomarkers of pancreatic ductal adenocarcinoma

Haruki Odaka1, Keiko Hiemori1, Asako Shimoda2, Kazunari Akiyoshi2 and Hiroaki Tateno1*

Abstract

Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest gastrointestinal cancers with a 5-year survival rate of less than 10%. Biomarkers for early PDAC detection are useful in treating patients with PDAC. Extracellular vesicles (EVs) are lipid-bound vesicles that are potential biomarkers of various diseases such as PDAC. In this study, we quantitatively measured the serum levels of EVs (CD63+ EVs) or platelet-derived EVs (CD41+ and CD61+ EVs) and evaluated their potential use as biomarkers of PDAC.

Methods: We measured the serum levels of CD63+, CD41+, CD61+ EVs using sandwich enzyme-linked immuno-sorbent assay based on Tim4 with specificity for phosphatidylserine on EVs in age- and sex-matched healthy controls (HCs, n = 39) and patients with PDAC (n = 39). We also examined the effect of tumor burden on the serum EV levels after surgical resection (n = 28). CA19-9, a clinical PDAC biomarker, was also measured for comparison.

Results: Serum levels of CD63+, CD41+, and CD61+ EVs were significantly increased in patients with PDAC compared to HCs. Receiver operating characteristic analysis revealed that CD63+ EVs exhibited the highest diagnostic performance to discriminate patients with PDAC from HCs (area under the curve (AUC): 0.846), which was comparable to CA19-9 (AUC: 0.842). CA19-9 showed lower AUC values in early stages (I–II, AUC: 0.814) than in late stages (III–IV, AUC: 0.883) PDAC. Conversely, CD63+, CD41+, and CD61+ EVs showed comparable AUCs between early- and late-stage PDAC. The combined use of CA19-9 and CD63+ EVs showed a higher diagnostic performance for early-stage PDAC (AUC: 0.903) than CA19-9. The serum levels of CD63+, CD41+, CD61+ EVs, and CA19-9 decreased significantly after surgical resection, demonstrating that EVs are increased in sera of patients depending on the tumor burden.

Conclusions: The serum levels of CD63+, CD41+, and CD61+ EVs are increased in patients with PDAC than HCs. Since CD63+ EVs showed a high AUC to discriminate patients with PDAC from HCs; they might be useful as potential biomarkers for PDAC.

Keywords: Pancreatic ductal adenocarcinoma, Extracellular vesicle, CD63, Platelet, Exosome, Biomarker

Introduction

Extracellular vesicles (EVs) are nan- to micrometer-sized vesicles surrounded by lipid bilayers, and released from all cells. EVs are currently categorized into three groups: exosomes of endocytic origin, microvesicles generated by plasma membrane budding, and apoptotic bodies [1], although there is no unique marker for these EVs.
Even the same cell was reported to release EVs with different compositions and functions [2]. EVs act as important mediators of intercellular communication in normal physiology and pathology [3]. EVs are also expected to be used for cancer detection, prognosis, and therapy [4].

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies and has a dismal prognosis with an overall 5-year survival rate of less than 10% [3]. The only curative therapy for PDAC is early detection followed by surgical resection [5]. Hence, early detection is important in improving the overall survival of patients with PDAC. EVs are potential diagnostic markers of PDAC. Previously, it was reported that glypican-1 (GPC1), a heparan sulfate proteoglycan, was specifically enriched on PDAC cell-derived EVs. GPC1⁺-EVs showed a high diagnostic performance to even early-stage PDAC [6]. miRNAs enriched with PDAC-derived EVs are intended to be used as important tools to diagnose PDAC [7, 8]. In addition, PDAC-derived EVs have been reported to promote proliferation, invasion, and metastasis of PDAC cells [7].

Previously we performed glycan profiling of EVs in sera of patients with Alzheimer’s disease (AD). EVs expressing CD61, a platelet marker, were only detected in sera of patients with AD, but not in healthy controls (HCs) [9]. Subsequent quantitative analysis using Tim4 (T Cell Immunoglobulin and Mucin Domain-containing Protein 4)-based sandwich enzyme-linked immunosorbent assay (ELISA) revealed that platelet marker (CD41, CD61)-positive EVs as well as tetraspanin (CD63 and CD9)-positive EVs are significantly increased in sera of patients with AD than those of HCs. Furthermore, among the EVs, CD63⁺-EVs showed the highest value for the area under the curve (AUC: 0.957) for discriminating patients with AD from HCs. However, we hypothesized that the upregulation of CD63⁺-EVs and platelet markers (CD41 and CD61)-positive EVs might not be an AD-specific pathology but common in various diseases such as cancers.

This study measured the serum levels of platelet-derived EVs (CD41⁺, CD61⁺-EVs) and CD63⁺-EVs in sera of patients with PDAC using Tim4-based sandwich ELISA. We clearly demonstrate for the first time that all of these EVs are increased in sera of patients with PDAC than HCs. The serum levels of these EVs decreased after surgical resection, suggesting that the upregulation of the serum EVs depends on tumor burden. Among the EVs, CD63⁺-EVs provided the highest AUC (0.846) to discriminate patients with PDAC from HCs. The combined use of CA19-9 and CD63⁺-EVs showed a higher diagnostic performance for early-stage PDAC (AUC: 0.903) than CA19-9. Hence, CD63⁺-EVs might be used as a potential biomarker for PDAC.

### Methods

#### Study population

This study involves two independent cohorts. The first cohort consists of 39 HCs and 39 patients with PDAC whose sera were obtained from BioIVT (Westbury, NY, USA) or Tsukuba University Hospital. The second cohort consists of 28 patients with PDAC whose sera were collected at presurgical operation and 30–90 days postoperation at Tsukuba University Hospital. All clinical samples were collected following the written informed consent. This study was approved by the medical ethics committee of Tsukuba University Hospital (H28-090) and the Committee for the Ethics on the Experiments with Human Derivative Samples of National Institute of Advanced Industrial Science and Technology. All experiments were performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. The demographic characteristics of participants are shown in Table 1 and Additional file 2: Table S1.

#### Characterization of Tim4-captured EVs

EVs were prepared from serum using MagCaptureTM Exosome Isolation Kit PS (Wako Pure Chemical Industries, Ltd., Osaka, Japan) following the manufacturer’s instructions. The size distribution of the prepared EVs were analyzed by nanoparticle tracking analysis (NTA). EVs were diluted to a concentration of 4–8 × 10⁸ particles per mL with PBS and analyzed in triplicates using a Nanosight LM10 system (Marvern Instruments Ltd., Worcestershire, UK) equipped with a blue laser. Morphology of EVs was examined using an HT7700-transmission electron microscopy (TEM). EVs (5 μL) were mixed with 4% paraformaldehyde (5 μL), incubated for 10 min on Formvar film for TEM (PVF-C10 STEM; Derivative Samples of National Institute of Advanced Industrial Science and Technology. All experiments were performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. The demographic characteristics of participants are shown in Table 1 and Additional file 2: Table S1.

#### Table 1 Participant’s characteristics of demographic data

|          | Cohort 1 | Cohort 2 |
|----------|----------|----------|
|          | HC  | PDAC |   |  |
| N        | 39  | 39   |   | 28  |
| Sex (male/female) | 33/6 | 34/5 | 1 | 15/13 |
| Age (year) | 59.05 ± 8.77b | 63.58 ± 10.83b | 0.06065 | 70.07 ± 7.850b |
| Clinical stage (N) |   |   |   |   |
| 0        | 0   | 2    |   |   |
| I        | 5   | 4    |   |   |
| II       | 18  | 21   |   |   |
| III      | 4   | 0    |   |   |
| IV       | 12  | 1    |   |   |

HC: Healthy control, PDAC: Pancreatic ductal adenocarcinoma

* p-value in Chi-squared test (sex) or Wilcoxon–Mann–Whitney test (age)

b Mean ± SD
and patients with PDAC (n = 39), who showed no significant difference in age (p = 0.06065) and sex (p = 1) between them (Table 1). CD63⁺-EVs showed significantly higher serum levels in patients with PDAC than HCs (p < 0.001) (Fig. 1a). The serum levels of CD41⁺-EVs and CD61⁺-EVs were moderately but significantly increased in patients with PDAC relative to HCs (p = 0.00649 and 0.0215, respectively) (Fig. 1b, c). We also confirmed that the serum level of CA19-9, a clinically used biomarker of PDAC, is significantly increased in patients with PDAC than HCs (p < 0.001) (Fig. 1d). These results demonstrate that CD63 and platelet markers (CD41, CD61)-positive EVs are increased in patients with PDAC.

**Sandwich ELISA**

Serum levels of EVs expressing either platelet markers (CD41, CD61) or EV marker (CD63) were quantified using the PS Capture Exosome ELISA Kit (Streptavidin HRP) (Wako Pure Chemical Industries, Ltd) as described previously [9]. Briefly, 100-fold diluted sera (100 μl) were incubated with Tim4-coated plates for 2 h at room temperature (RT). After washing, a biotinylated antibody for each marker protein was incubated for 1 h at RT. Then, horseradish peroxidase (HRP)-labeled streptavidin was incubated for 2 h at RT followed by washing. After incubation with 3,3',5,5'-tetramethylbenzidine solution for 30 min, a stop solution was applied. An optical density (OD) was measured at 450 nm as the dominant wavelength and 620 nm as the secondary wavelength. The following antibodies were biotinylated and used for sandwich assays: anti-CD41 mAb (1 μg/mL, clone No. 745201; R&D Systems), anti-CD61 mAb (1 μg/mL, clone No. 256809; R&D Systems), anti-CD63 (component of PS Capture Exosome ELISA Kit; Wako).

CA19-9 was measured using Accuanseed CA19-9 reagents (FUJIFILM Wako Pure Chemical Co., Osaka, Japan).

**Statistical analysis**

Wilcoxon–Mann–Whitney test, Wilcoxon signed rank test, Chi-square test, Pearson’s product-moment correlation, Spearman’s rank correlation, DeLong’s test, and receiving operator curve (ROC) analysis were calculated using EZR on R commander version 1.41 [10]. Statistical significance was set at *p*-value < 0.05. The summary of power calculation when the alpha was set at 0.05 in each age diameters of Tim4-captured EVs was 170 ± 11.9 nm (average ± SD). We analyzed cohort 1 with HCs (n = 39) and patients with PDAC (n = 39), who showed no significant difference in age (*p* = 0.06065) and sex (*p* = 1) between them (Table 1). CD63⁺-EVs showed significantly higher serum levels in patients with PDAC than HCs (*p* < 0.001) (Fig. 1a). The serum levels of CD41⁺-EVs and CD61⁺-EVs were moderately but significantly increased in patients with PDAC relative to HCs (*p* = 0.00649 and 0.0215, respectively) (Fig. 1b, c). We also confirmed that the serum level of CA19-9, a clinically used biomarker of PDAC, is significantly increased in patients with PDAC than HCs (*p* < 0.001) (Fig. 1d). These results demonstrate that CD63 and platelet markers (CD41, CD61)-positive EVs are increased in patients with PDAC.

**Receiver operating characteristic (ROC) analysis**

To evaluate the diagnostic ability of each marker-positive EV, we generated an ROC curve and quantified the AUC. Among the three types of EVs, CD63⁺-EVs showed the highest AUC value (0.846) and could discriminate patients with PDAC from HCs with high sensitivity (0.821) and specificity (0.846) when the cut-off value was set at 0.016 (Fig. 2a, Table 2). The AUC values of CD41⁺-EVs and CD61⁺-EVs were 0.678 and 0.652, respectively, showing moderate performance as diagnostic markers (Fig. 2b, c, Table 2). The AUC value of CA19-9 (0.842) was similar to that of CD63⁺-EVs (*p* = 0.945, Fig. 2d, Table 2), suggesting that CD63⁺-EVs show a similar diagnostic performance to discriminate PDAC from HCs.

**Correlation analysis between marker-positive EVs and CA19-9**

To evaluate the strength of the relationship between serum EVs and CA19-9, we performed a non-parametric Spearman’s correlation analysis. As expected, CD41⁺-EVs and CD61⁺-EVs showed the highest correlation between them (*ρ* = 0.742), as both could be secreted from the same origin (Fig. 3a). CD41⁺-EVs and CD61⁺-EVs showed moderate correlation with CD63⁺-EVs (*ρ* = 0.687 and *ρ* = 0.574, respectively) (Fig. 3b, c). Conversely, all of the EVs (CD63⁺-EVs and CD61⁺-EVs) showed only a low correlation with CA19-9 (*ρ* = 0.376, *ρ* = 0.213, *ρ* = 0.243, respectively) (Fig. 3d–f). A similar result was also observed in the parametric Pearson’s correlation analysis (see Additional file 1: Fig. S2). These results suggest that the serum EVs and CA19-9 are independent biomarkers of PDAC pathology.

**Diagnostic performance of the serum EVs in early- and late-stage PDAC**

Early diagnosis of PDAC is crucial to improving the prognosis of PDAC. It has been reported that the diagnostic performance of CA19-9 in early-stage PDAC is lower
than that in late-stage one [11]. Consistently, the serum level of CA19-9 in patients with early-stage (stage I–II) PDAC was significantly lower than that in late-stage (stage III–IV) patients with PDAC (Fig. 4a). ROC analysis of CA19-9 values also showed lower AUC for early-stage PDAC (AUC: 0.814) compared to late-stage PDAC (AUC: 0.883) to differentiate from HCs (Table 2). In contrast, the serum levels of CD63\(^+\)-EVs, CD41\(^+\)-EVs, and CD61\(^+\)-EVs in early-stage PDAC were comparable to those in late-stage PDAC with \(p > 0.05\) (\(p = 0.746\), \(p = 0.855\), \(p = 1\), respectively, Fig. 4). The AUC values of CD63\(^+\)-EVs, CD41\(^+\)-EVs, and CD61\(^+\)-EVs in early-stage PDAC (0.858, 0.685, 0.657, respectively) were also similar to those for late-stage PDAC (0.83, 0.668, 0.644, respectively) (Table 2). These results demonstrate that the serum levels of EVs are similar between early- and late-stage PDAC.

**Combinational use of CD63\(^+\)-EVs and CA19-9 for early diagnosis of PDAC**

The low correlation coefficient of serum levels between CA19-9 and CD63\(^+\)-EVs suggested that the combined use of these markers may compensate for the false-negative with each other and improve the diagnostic performance. Therefore, we examined the diagnostic performance of cobitional use of CA19-9 and CD63\(^+\)-EVs. In order to weight the value of CA19-9 and CD63\(^+\)-EVs equally, we used the value obtained by multiplying these two values as $CA19-9 \times CD63^+\text{-EVs}$. The value of $CA19-9 \times CD63^+\text{-EVs}$ was significantly higher in patients with PDAC than in HCs (Fig. 5a). Remarkably, $CA19-9 \times CD63^+\text{-EVs}$ showed a significantly higher AUC for early-stage PDAC (stage I–II, AUC: 0.906) than CA19-9 (AUC: 0.814, \(p = 0.033\)) (Fig. 5b, c). In contrast, the AUC values of $CA19-9 \times CD63^+\text{-EVs}$ for all-stage (0.903) and late-stage PDAC (0.899) were comparable to those of CA19-9 (all stage: AUC = 0.842, \(p = 0.124\); late-stage: AUC = 0.883, \(p = 0.809\)) (Table 2). These results indicate that the combined use of CD63\(^+\)-EVs and CA19-9 improves the diagnostic performance for early-stage PDAC (I–II).

**Influence of surgical resection on the serum levels of EVs**

Finally, we investigated the effect of surgical resection on the serum levels of EVs. The serum levels of CA19-9, CD63\(^+\)-EVs, CD41\(^+\)-EVs and CD61\(^+\)-EVs were significantly decreased after surgical resection (Fig. 6a–d).
Of 28 patients with PDAC, 14 patients had recurrence and 14 patients had non-recurrence after surgical resection. We examined whether preoperative EV levels predict the recurrence of PDAC. Recurrence group showed a trend to higher CD41$^+$-EV and and CD61$^+$-EV levels in comparison with non-recurrence group, but not statistically significant (Additional file 1: Fig. S3, $p = 0.0620$ and $0.0620$, respectively).

We further analyzed the change in the values of EVs and CA19-9 before and after operation in each patient (see Additional file 1: Fig. S4). The serum levels of EVs and CA19-9 fluctuated in the same trend before and after surgical resection in most patients except for patient’s No. 7, 8, and 16. This result suggests that the serum levels of EVs reflect tumor burden similar to CA19-9. The inconsistency in patients No. 7 and 8 is likely due to the low serum level of CA19-9 in the preoperative stage (4.8 and 3.5 unit/ml, respectively; threshold: 11.7), while the serum level of CD63$^+$-EVs was high at this stage (0.0596 and 0.0216, respectively; threshold: 0.016). These results demonstrate that the serum levels of platelets (CD41 and CD61) and universal marker (CD63)-positive EVs reflect the tumor burden before and after surgical resection.

![Fig. 2](image-url) ROC curve of EVs and CA19-9. ROC curves are shown for CD63$^+$-EVs (a), CD41$^+$-EVs (b), CD61$^+$-EVs (c), and CA19-9 (d). Area under curve (AUC) and its 95% confidence interval are indicated in the figure. Dot indicates the cut-off value which maximizes the sum of sensitivity and specificity.
### Table 2 Summary of ROC analysis

|                      | AUC (95% CI)       | Threshold | Specificity | Sensitivity | Sensitivity p-valuea (vs CA19-9) |
|----------------------|--------------------|-----------|-------------|-------------|----------------------------------|
| **All stage**        |                    |           |             |             |                                  |
| CA19-9               | 0.842 (0.755–0.930)| 11.7      | 0.769       | 0.846       |                                  |
| CD63+EVs             | 0.846 (0.752–0.941)| 0.016     | 0.846       | 0.821       | 0.945                            |
| CD41+EVs             | 0.678 (0.552–0.804)| 0.079     | 0.744       | 0.718       | 0.0290                           |
| CD61+EVs             | 0.652 (0.527–0.776)| 0.045     | 0.641       | 0.718       | 0.00932                          |
| CD63+EVs × CA19-9    | 0.903 (0.823–0.984)| 0.136     | 0.872       | 0.897       | 0.124                            |
| **Early stage (I–II)** |                  |           |             |             |                                  |
| CA19-9               | 0.814 (0.699–0.929)| 11.7      | 0.769       | 0.870       |                                  |
| CD63+EVs             | 0.858 (0.745–0.971)| 0.011     | 0.0769      | 0.913       | 0.557                            |
| CD41+EVs             | 0.685 (0.529–0.841)| 0.079     | 0.744       | 0.738       | 0.197                            |
| CD61+EVs             | 0.657 (0.51–0.804) | 0.045     | 0.641       | 0.739       | 0.0992                           |
| CD63+EVs × CA19-9    | 0.906 (0.802–1)    | 0.264     | 0.923       | 0.87        | 0.0330                           |
| **Late-stage (III–IV)** |                 |           |             |             |                                  |
| CA19-9               | 0.883 (0.773–0.993)| 36        | 0.949       | 0.75        |                                  |
| CD63+EVs             | 0.83 (0.689–0.972)| 0.018     | 0.846       | 0.812       | 0.517                            |
| CD41+EVs             | 0.668 (0.495–0.842)| 0.081     | 0.744       | 0.625       | 0.00769                          |
| CD61+EVs             | 0.644 (0.468–0.82)| 0.048     | 0.667       | 0.688       | 0.00236                          |
| CD63+EVs × CA19-9    | 0.899 (0.773–1)    | 0.136     | 0.872       | 0.875       | 0.809                            |

ROC: Receiver operating characteristic, AUC: area under curve, CI: confidence interval

*p-value in DeLong’s test

---

**Fig. 3** Correlation analysis between EVs and CA19-9. Spearman’s rank correlation coefficient tests between CD41+EVs and CD61+EVs (a), CD41+EVs and CD63+Evs (b), CD63+Evs and CD61+Evs (c), CD63+Evs and CA19-9 (d), CD41+Evs and CA19-9 (e), CD61+Evs, and CA19-9 (f) were shown. p and p-values are indicated in the figure.
Discussion

There are many reports on the functions and medical applications of PDAC-derived EVs [7]. Here we have demonstrated that both platelet markers (CD41, CD61)-positive EVs and CD63-positive EVs are increased in sera of patients with PDAC. The serum levels of CD63

Fig. 4 Comparison of the values of EVs and CA19-9 between early and late-stage PDAC. CA19-9 (a), CD63+-EVs (b), CD41+-EVs (c), and CD61+-EVs (d) were shown in early (I–II, n = 23) and late (III–IV, n = 16) clinical stage of patients with PDAC. p-values obtained by Wilcoxon–Mann–Whitney test are indicated in the figure.

Fig. 5 Combined use of CD63+-EVs and CA19-9 for detection of early-stage PDAC. The values of CD63+-EVs × CA19-9 were calculated by multiplying the OD values of CD63+-EVs and CA19-9 level. The values of CD63+-EVs × CA19-9 in HCs (n = 39) and PDACs (n = 39) (a) or early-stage PDACs (stage I–II, n = 23) (b) were shown. p-values obtained by Wilcoxon–Mann–Whitney Test are indicated in the figure. (c) Comparison of ROC curve of CA19-9 and CD63+-EVs × CA19-9 in early-stage sets consisting of 39 HCs and 23 early-stage PDAC. Solid and dotted line indicates CD63+-EVs × CA19-9 and CA19-9, respectively. p-values obtained by DeLong's test are indicated in the figure.

Stage

| CA19-9 (Unit/ml) | p-value |
|------------------|---------|
| Stage I-II       | 0.0289  |
| Stage III-IV     | 0.746   |

Stage

| CD63+-EV (OD450/620) | p-value |
|----------------------|---------|
| Stage I-II           | 0.855   |
| Stage III-IV         | 1.000   |

---

Discussion

There are many reports on the functions and medical applications of PDAC-derived EVs [7]. Here we have demonstrated that both platelet markers (CD41, CD61)-positive EVs and CD63-positive EVs are increased in sera of patients with PDAC. The serum levels of CD63+-EVs

---

Discussion

There are many reports on the functions and medical applications of PDAC-derived EVs [7]. Here we have demonstrated that both platelet markers (CD41, CD61)-positive EVs and CD63-positive EVs are increased in sera of patients with PDAC. The serum levels of CD63+-EVs
showed diagnostic performance comparable to CA19-9, while there is a low correlation between them. The combined use of CA19-9 and CD63\(^+\)-EVs showed a higher AUC for early-stage PDAC compared to CA19-9. Interestingly, the serum EVs levels reflected the tumor burden, indicating the association of this EV production with tumors.

Among the serum EVs measured in this study, CD63\(^+\)-EVs showed the highest performance in discriminating patients with PDAC and HCs. CD63, a member of the tetraspanin family, is highly enriched in the exosome subpopulation, thus, generally recognized as an exosome marker [12]. The serum CD63\(^+\)-EV levels reflected the tumor burden since they decreased after surgical resection and fluctuated together with CD19-9 levels. Recently, Hoshino et al. investigated the proteomic profile of EVs and extracellular particles in 426 human samples from tissue explants, plasma, and other body fluids [13]. CD63\(^+\)-EVs were rarely detected in either human or mouse origin through biofluids (plasma, serum, lymphatic fluid). This observation is consistent with our results that the serum levels of CD63\(^+\)-EVs in HCs are low [9]. Consistently, CD63\(^+\)-EVs were previously reported to be increased in colorectal cancer patients compared to HCs [14]. We previously reported that CD63\(^+\)-EVs are increased in sera of AD patients. Therefore CD63\(^+\)-EVs was shown to respond to neurodegenerative disorders as well as cancers.

One of the origins of CD63\(^+\)-EVs is believed to be platelets. In sera of both PDAC and AD patients, CD63\(^+\)-EVs showed a positive correlation with CD41\(^+\)-EVs and CD61\(^+\)-EVs derived from platelets. The serum levels of CD41\(^+\)-EVs and CD61\(^+\)-EVs were significantly increased in sera of patients with PDAC and decreased after surgical resection. It was notable that CD41\(^+\)-EVs and CD61\(^+\)-EVs fluctuated with the same trend as CD19-9 before and after surgical resection. Therefore, platelet-derived EVs might be directly or indirectly associated with PDAC. Growing evidence demonstrates that activated platelet and platelet-derived EVs have a critical role in cancer metastasis [15]. “Tumor-educated platelets” are involved in the progression and spread of several tumors and can be used as potential biomarkers for cancer detection [16, 17]. An in vitro study demonstrated that cancer cells, including PDAC cell lines, can activate platelets [18]. Therefore, EVs released from tumor-educated platelets might be related to cancer progression and metastasis. Consistently, the formation of the aggregates of
CD63+ EVs demonstrated high diagnostic performance in discriminating PDAC from HCs. Thus, there are potential benefits for the clinical use of CD63+ EVs. First, combined with CA19-9, CD63+ EVs can increase the performance to discriminate early-stage patients with PDAC, as shown in Fig. 5c. Second, CD63+ EVs can be used to evaluate the therapeutic effects of surgical and drug treatments. As described above; however, CD63+ EVs are not specific to PDAC but increase in other diseases [9]. Therefore, we hypothesize that CD63+ EVs might increase in sera of patients with various diseases. In our preliminary experiments it was observed that serum levels of CD63+ EVs increased in sera of patients with various cancers, inflammatory diseases, and neurodegenerative/mental disorders. Although the mechanism by which CD63+ EVs increases in blood is unclear, it might be linked to disease-related inflammation. In this sense, CD63− EVs could be used as an inflammatory-associated disease biomarker. To apply CD63+ EVs for diagnosis, in future studies we need to understand the mechanism by which CD63+ EVs increases in sera of patients and their functions.

Conclusions
In this study, we showed that the serum levels of universal CD63+ EVs and platelet-derived EVs (CD41+ EVs, CD61+ EVs) are increased in patients with PDAC than HCs. The serum levels of CD63+, CD41+, and CD61+ EVs reflected the tumor burden in patients with PDAC. Since CD63+ EVs showed a high AUC to discriminate patients with PDAC from HCs; they might be useful as potential biomarkers for PDAC.

Abbreviations
PDAC: Pancreatic ductal adenocarcinoma; EV: Extracellular vesicle; AUC: Area under curve; AD: Alzheimer’s disease; HC: Healthy control; ELISA: Enzyme-linked immunosorbent assay; HRP: Horseradish peroxidase; OD: Optical density; ROC: Receiving operator curve; PRE-OP: Preoperation; POST-OP: Postoperation.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12876-022-02228-7.

Acknowledgements
We thank Drs. Osamu Shimomura and Tatsuya Oda for the use of serum samples.

Authors’ contributions
HT conceived and designed the project, interpreted the data, and wrote the paper. HO analyzed and interpreted the data, and wrote the paper. KS, AS, KA performed experiments and analyzed the data. All authors read and approved the final manuscript.

Funding
This work was supported in part by JST-CREST (Grant Number JPMJCR17H2), AMED-Prime (Grant number 21gm6010018h0004), and The Kurata Grants from The Hitachi Global Foundation.

Availability of data and materials
The datasets used for the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
This study was approved by the medical ethics committee of University of Tsukuba Hospital (H28-090) and the Committee for the Ethics on the Experiments with Human Derivative Samples of National Institute of Advanced Industrial Science and Technology. All serum samples were collected after informed consent. All experiments were performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Cellular and Molecular Biotechnology Research Institute, National Institute of Advanced Industrial Science and Technology, 1-1-1 Higashi, Tsukuba, Ibaraki 305-8566, Japan. 2 Department of Polymer Chemistry, Graduate School of Engineering, Kyoto University, Katsura, Nishikyo-ku, Kyoto 615-8510, Japan.

Received: 20 October 2021 Accepted: 21 March 2022

References
1. Hu W, Liu C, Bi ZY, Zhou Q, Zhang H, Li LL, Zhang J, Zhu W, Song YY, Zhang F, et al. Comprehensive landscape of extracellular vesicle-derived RNAs in cancer initiation, progression, metastasis and cancer immunology. Mol Cancer. 2020;19(1):102.
2. Maas SLN, Breakefield XO, Weaver AM. Extracellular vesicles: unique intercellular delivery vehicles. Trends Cell Biol. 2017;27(3):172–88.
3. Chen K, Wang Q, Kormann M, Tian X, Yang Y. The role of exosomes in pancreatic cancer from bench to clinical application: an updated review. Front Oncol. 2021;11:644358.
4. Chen IH, Xue L, Hsu CC, Paez JS, Pan L, Andaluz H, Wendt MK, Iliuk AB, Zhu JK, Tao WA. Phosphoproteins in extracellular vesicles as candidate markers for breast cancer. Proc Natl Acad Sci USA. 2017;114(12):3175–80.
5. Wiest NE, Moktan VP, Oman SP, Chirilă RM. Screening for pancreatic cancer: a review for general clinicians. Rom J Intern Med. 2020;58(3):119–28.
6. Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, LeBleu VS, Mitterodt EA, Wertz J, Rahbari N, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015;523(7559):177–82.
7. Liu H, Qiao S, Fan X, Gu Y, Zhang Y, Huang S. Role of exosomes in pancreatic cancer. Oncol Lett. 2021;21(4):298.
8. Ariston Gabriel AN, Wang F, Jiao Q, Yvette U, Yang X, Al-Ameri SA, Du L, Wang YS, Wang C. The involvement of exosomes in the diagnosis and treatment of pancreatic cancer. Mol Cancer. 2020;19(1):132.

9. Odaka H, Hiemori K, Shimoda A, Akiyoshi K, Tatemoto H. Platelet-derived extracellular vesicles are increased in sera of Alzheimer’s disease patients, as revealed by Tim4-based assays. FEBS Open Bio. 2021;11(3):741–52.

10. Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transpl. 2013;48(3):452–8.

11. Brezglyte G, Shah V, Jach D, Crnogorac-Jurcevic T. Non-invasive biomarkers for earlier detection of pancreatic cancer—a comprehensive review. Cancers (Basel). 2021;13(11):2722.

12. Kowal J, Arras G, Colombo M, Jouve M, Morath JP, Primdal-Bengtson B, Dingl F, Loew D, Tkach M, Théry C. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. Proc Natl Acad Sci USA. 2016;113(8):E968–977.

13. Hoshino A, Kim HS, Bojmar L, Gyan KE, Gioffi M, Hernandez J, Zambiris CP, Rodrigues G, Molina H, Heissel S, et al. Extracellular vesicle and particle biomarkers define multiple human cancers. Cell. 2020;182(4):1044–1061. e1018.

14. Wei P, Wu F, Kang B, Sun X, Heskia F, Pachot A, Liang J, Li D. Plasma extracellular vesicles detected by single molecule array technology as a liquid biopsy for colorectal cancer. J Extracell Vesicles. 2020;9(1):1809765.

15. Plantureux L, Mégé D, Crescence L, Dignat-George F, Dubois C, Panicot-Dubois L. Impacts of cancer on platelet production, activation and education and mechanisms of cancer-associated thrombosis. Cancers (Basel). 2018;10(11):441.

16. Best MG, Wesseling P, Wurdinger T. Tumor-educated platelets as a noninvasive biomarker source for cancer detection and progression monitoring. Cancer Res. 2018;78(13):3407–12.

17. In’t Veld S, Wurdinger T. Tumor-educated platelets as a noninvasive biomarker source for cancer detection and progression monitoring. Blood. 2019;133(22):2359–64.

18. Heinmöller E, Schopp T, Kisker O, Simon B, Setz R, Weinel RJ. Tumor cell-induced platelet aggregation in vitro by human pancreatic cancer cell lines. Scand J Gastroenterol. 1995;30(10):1008–16.

19. Gouban HA, Kotb RR, Stakiw J, Emara ME, Burnouf T. Regulation of tumor growth and metastasis: the role of tumor microenvironment. Cancer Growth Metastasis. 2014;79–18.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.